Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the general formula (I)



(I)

wherein

R^1 is ~~selected from~~ hydrogen, a branched or straight C_1-C_6 alkyl, C_1-C_6 alkenyl, C_3-C_8 cycloalkyl, C_4-C_8(alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; C_6-C_{10} aryl; or heteroaryl having from 5 to 10 atoms selected from ~~any of~~ C, S, N and/or O, wherein ~~the~~ said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents ~~independently~~ selected from ~~any of~~ hydrogen, CH_3, $(CH_2)_pCF_3$, halogen, $CONR^5R^4$, $COOR^5$, COR^5, $(CH_2)_pNR^5R^4$, $(CH_2)_pCH_3$, $(CH_2)_pSOR^5R^4$, $(CH_2)_pSO_2R^5$, $(CH_2)_pSO_2NR^5R^4$ and $(CH_2)_pOR^5$, wherein p is 0, 1 or 2; (C_1-C_2 alkyl)-(C_6-C_{10} aryl); or (C_1-C_2 alkyl)heteroaryl, ~~the~~wherein said heteroaryl ~~moieties having~~ has from 5 to 10 atoms selected from ~~any of~~ C, S, N and/or O, and wherein ~~the~~ said aryl and/or heteroaryl may optionally and independently be substituted by 1 or 2 substituents ~~independently~~ selected from ~~any of~~ hydrogen, CH_3, ~~$-(CH_2)_qCF_3$~~, $-(CH_2)_qCF_3$, halogen, $-CONR^5R^4$, $-COOR^5$, $-COR^5$, $-(CH_2)_qNR^5R^4$, $-(CH_2)_qCH_3$, $-(CH_2)_qSOR^5R^4$, $-(CH_2)_qSO_2R^5$, $-(CH_2)_qSO_2NR^5R^4$, and ~~$-(CH_2)_pOR^5$~~ $-(CH_2)_qOR^5$, wherein q is 0, 1 or 2; and

,

,

~~;~~ or



, wherein R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, and R^{24} is each and independently selected from hydrogen, C_1-C_6 alkyl, and ~~or~~ C_1-C_6 alkenyl;

R^2 and R^3 is each and independently selected from hydrogen and ~~or~~ C_1-C_6 alkyl;

A is ~~selected from~~



, wherein the phenyl ring of ~~each~~ A is ~~substituent may be~~ optionally and independently substituted by 1 or 2 substituents Z^1 and Z^2 each and independently selected from hydrogen, CH_3, ~~$-(CH_2)_rCF_3$~~ $-(CH_2)_rCF_3$, halogen, $-CONR^6R^7$, $-CO_2R^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;

Q is C_5-C_6 hydroaryl; ~~or~~ heterohydroaromatic having 5 or 6 atoms selected from ~~anyone of~~ C, S, N and/or O; C_5-C_6 cycloalkyl, ~~or;~~ or heterocycloalkyl having 5 or 6 atoms selected from ~~any one of~~ C, N, O and/or S; and wherein each Q ~~may~~ is optionally ~~be~~ substituted by a subsitutent Z^1 and Z^2 as defined above;

B is ~~selected from~~ phenyl, ~~or~~ naphthyl, wherein the phenyl and naphthyl is optionally and independently substituted by 1 or 2 substituents ~~independently~~ selected from hydrogen, CH_3, $-(CH_2)_tCF_3$, halogen, $-(CH_2)_tCONR^5R^4$, $-(CH_2)_tNR^5R^4$, $-(CH_2)_tCOR^5$, $-(CH_2)_tCOOR^5$, $-OR^5$, $-(CH_2)_tSOR^5$, $-(CH_2)_tSO_2R^5$, and $-(CH_2)_tSO_2NR^5R^4$, ~~and~~ wherein t is 0, 1, 2 or 3; and

R^4, R^5, R^6, and R^7 is each and independently selected from hydrogen; a branched or straight C_1-C_6 alkyl; C_1-C_6 alkenyl; C_3-C_8 cycloalkyl; and C_4-C_8(alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl;

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, isoforms and prodrugs thereof.

2. (currently amended) A compound of the formula (I) according to claim 1, wherein



A is ~~selected from~~ ;, wherein the phenyl ring of ~~each~~ A is ~~substituent may be~~ optionally and independently substituted at any position of the phenyl ring by 1 or 2 substituents Z^1 and Z^2 which ~~are~~ is each and independently selected from hydrogen, CH_3, ~~$-(CH_2)_qCF_3$~~ $-(CH_2)_qCF_3$, halogen, $-CONR^6R^7$, $-COOR^6$, $-COR^6$, $-(CH_2)_rNR^6R^7$, $-(CH_2)_rCH_3$, $-(CH_2)_rSOR^6$, $-(CH_2)_rSO_2R^6$ and $-(CH_2)_rSO_2NR^6R^7$, wherein r is 0, 1, or 2;

Q is ~~selected from~~ morpholine, piperidine, or ~~and~~ pyrrolidine;

R^1 is ~~selected from~~ hydrogen;, a branched or straight C_1-C_4 alkyl;, C_3-C_5 cycloalkyl;, C_4-C_8 (alkyl-cycloalkyl), wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; and C_6-C_{10} aryl; ~~and~~ or heteroaryl having from 5 to 6 atoms selected from ~~any of~~ C, S, N and/or O, ; ~~and~~ wherein the aryl and/or heteroaryl ~~may~~ is optionally and independently ~~be~~ substituted by 1 or 2 substituents ~~independently~~ selected from ~~any of~~ hydrogen, CH_3, $-(CH_2)_pCF_3$, halogen, $-CONR^5R^4$, $-COOR^5$, $-COR^5$, $-(CH_2)_pNR^5R^4$, $-(CH_2)_pCH_3$, $-(CH_2)_pSOR^5R^4$, $-(CH_2)_pSO_2R^5$, and $-(CH_2)_pSO_2NR^5R^4$, wherein p is 0, 1 or 2;

B is ~~selected from~~ phenyl, ~~and~~ or naphthyl, wherein the phenyl and naphthyl is ~~each~~ optionally and independently substituted by 1 or 2 substituents ~~independently~~ selected from hydrogen, CH_3, CF_3, halogen, $-(CH_2)_qCONR^5R^4$, $-(CH_2)_qNR^5R^4$, $-(CH_2)_qCOR^5$, $-(CH_2)_qCO_2R^5$, and $-OR^5$; wherein q is 0 or 1; ~~and wherein~~

R^4, R^5, R^6, and R^7, is each and independently selected from hydrogen, a branched or straight C_1-C_6 alkyl, C_1-C_6 alkenyl, C_3-C_8 cycloalkyl, and C_4-C_8(alkyl-cycloalkyl) wherein alkyl is C_1-C_2 alkyl and cycloalkyl is C_3-C_6 cycloalkyl; and

R^2 and R^3 is each and independently selected from hydrogen ~~or~~ and methyl.

3. (canceled)

4. (currently amended) A compound of the formula (I) according to claim 1, which compound is



, wherein R is morpholine, piperidine or pyrrolidine~~;~~.

5. (canceled).

6. (currently amended) A compound according to claim 1~~any of the preceding claims~~, in form of its hydrochloride, sulfate, tartrate or citrate salts.

7-14. (canceled)

15. (currently amended) A compound according to claim 1, wherein said compound ~~further characterised in that it~~ is isotopically labelled.

16. (canceled).

17. (original) An isotopically labelled compound of the formula (I) of claim 1.

18. (canceled).

19. (original) A pharmaceutical composition comprising a compound of the formula (I) according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

20-26. (canceled)

27. (new) A compound according to claim 4, in form of its hydrochloride, sulfate, tartrate or citrate salts.

28. (new) A pharmaceutical composition comprising a compound of the formula (I) according to claim 4 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

29. (new) A compound according to claim 2, wherein B is a phenyl substituted by 1 substituent selected from halogen.

30. (new) A compound according to claim 29, wherein the halogen is fluorine.

31. (new) A compound according to claim 30, wherein said phenyl is substituted at the meta position by said fluorine.

31. (new) A compound according to claim 29, wherein Z^1, Z^2, and R^1 is each and independently H; and R^2 and R^3 is each and independently selected from H and CH_3.

32. (new) A compound according to claim 31, wherein Z^1, Z^2, R^1, R^2, and R^3 is each and independently H.

33. (new) A compound according to claim 29, wherein Z^1, Z^2, R^1, R^2, and R^3 is each and independently H.

34. (new) A compound according to claim 4, wherein said compound is isotopically labeled.

35. (new) A compound according to claim 1, wherein the compound is selected from:
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-morpholin-4-yl-methanone;
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-piperidin-1-yl-methanone; and
4-[(3-fluorophenyl)-piperidin-4-yl-methyl]-phenyl-pyrolidin-1-yl-methanone.